^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + letrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LBA28 - A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
Published date:
09/19/2020
Excerpt:
Eligible pts had ECOG PS 0/1, histologically confirmed endometrioid EC that was ER+….L + palbociclib significantly improved PFS compared with L + placebo: median 8.3 vs. 3.0 months, respectively...Disease control rate at 24 weeks: 64% vs. 38%....The L + palbociclib combination demonstrated clinically meaningful improvement in PFS...
Trial ID:
